Results 211 to 220 of about 311,006 (351)
In this study, a targeting PFKFB4 biomimetic codelivery system is developed to improve paclitaxel efficacy by inducing ferroptosis in SCLC. This system enhances immune cell infiltration and cytokine secretion, activating anti‐tumor immunity. Combined with anti‐PD‐L1, it boosts immune responses, offering a novel therapeutic strategy for overcoming ...
Xiang Liu+9 more
wiley +1 more source
This study develops TMEclassifier, a machine‐learning tool that classifies cancers into three distinct subtypes—Immune exclusive (IE), immune suppressive (IS), and immune activated (IA)—which exhibit significant heterogeneity and necessitate customized therapeutic strategies.
Dongqiang Zeng+27 more
wiley +1 more source
Engineered Tissue Models to Decode Host–Microbiota Interactions
Host–Microbiota interactions in the human body. Created in BioRender. Ghezzi, C. (2025) https://BioRender.com/ihivskg. Abstract A mutualistic co‐evolution exists between the host and its associated microbiota in the human body. Bacteria establish ecological niches in various tissues of the body, locally influencing their physiology and functions, but ...
Miryam Adelfio+5 more
wiley +1 more source
This study reports an innovative strategy to improve the safety of OMVs by shielding them with a sophisticated shell composed of DaFe shell and Au nanoparticles, which not only reduces the toxicity of OMVs during circulation but also enables rapid release of these therapeutically active components in tumor for combined therapy involving glucose ...
Fan Zhang+11 more
wiley +1 more source
A theranostic nanoplatform is formulated with NIR‐II emissive lipophilic cyanine dye IRC18 to intercalate into genetically engineered IL12/CSF1R‐macrophage membrane‐liposome hybrid nanovesicles, which assists to achieve blood–brain barrier crossing, glioblastoma targeting, NIR‐II fluorescence imaging, image‐guided membrane‐targeted mild photothermal ...
Pengfei Chen+10 more
wiley +1 more source
Background: Dose-dense sequential (dds) chemotherapy has changed the clinical outcome of patients with early breast cancer (BC). To investigate the impact of dose intensity (DI) in the adjuvant setting of BC, this observational trial (HE 10/10) was ...
Foteinos-Ioannis Dimitrakopoulos+29 more
doaj
The study develops engineered exosomes (EmDEX@GA) for locoregional immunomodulation of tumor‐draining lymph node (TDLN). EmDEX@GA can actively target to TDLN and remodel its immunosuppressive microenvironment through the synergistic effects of PD‐1/PD‐L1 blockade and STING pathway activation, subsequently enhance anti‐tumor immunity and suppress tumor ...
Yizhen Wang+12 more
wiley +1 more source
Microsatellite‐stable (MSS) colorectal cancer (CRC) resists immunotherapy. PRMT5 inhibition enhances CPT‐11 sensitivity, inducing a PMS2‐deficient‐like state and cytosolic dsDNA release, which activates the cGAS‐STING pathway to promote anti‐tumor immunity. However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition
Jiang Zhu+10 more
wiley +1 more source
The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis. [PDF]
Yaprak Bayrak B+4 more
europepmc +1 more source
Synthetic gene circuits regulated by bezafibrate are developed to express tumor antigens and PD‐L1 nanobody (PD‐L1nb), enhancing cancer immunotherapy. Delivered via HEK293T cells, ESCs, or directly injected the plasmids containing the circuit into the tumor, the circuits reduce tumor growth, boost CD8+ T cells, and minimize T cell exhaustion.
Meiling Jin+3 more
wiley +1 more source